



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	HIV-1 p51 Reverse Transcriptase Recombinant Protein
Catalog Number:	2896
Lot Number:	170217
Provided:	25 µg of purified protein at 1 mg/ml in 50 mM Tris-HCl, pH 7.0, 25 mM NaCl, 1 mM EDTA, 50% (v/v) Glycerol
Molecular Weight:	51 kDa
Purity:	>85% by Coomassie Blue staining
Description:	A full length HIV-1 p51 RT subunit recombinant protein derived from a patient sample.
Special Characteristics:	<p>This HIV-1 reverse transcriptase protein is produced in an E. coli expression system and purified by IMAC and cation exchange chromatography. This protein contains an N-terminal 6XHis-tag and is non-glycosylated. The integrity of the protein is determined immunologically with anti-RT antibodies. It is weakly active as a DNA polymerase if salt is reduced from standard RT assay buffer. This protein can also be used for antibody production.</p> <p>Donor provided sequence</p>
Recommended Storage:	Keep the reagent at -80°C. Avoid freeze-thaw cycles as reagent degradation may result.
Contributor:	Dr. Stuart Le Grice
References:	<p>K. J. Howard, K. B. Frank, I. S. Sim and S. F. Le Grice. (1991). Reconstitution and properties of homologous and chimeric HIV-1.HIV-2 p66.p51 reverse transcriptase. J Biol Chem, 266(34), 23003-9. PUBMED</p> <p>P. S. Jacques, B. M. Wohrl, K. J. Howard and S. F. Le Grice. (1994). Modulation of HIV-1 reverse transcriptase function in "selectively deleted" p66/p51 heterodimers. J Biol Chem, 269(2), 1388-93. PUBMED</p> <p>S. F. Le Grice, C. E. Cameron and C. J. Berkebile. (1995). Purification and</p>

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

S. F. Le Grice, C. E. Cameron and S. J. Benkovic. (1995). Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. *Methods Enzymol*, 262, 130-44. [PUBMED](#)

S. F. Le Grice, T. Naas, B. Wohlgensinger and O. Schatz. (1991). Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. *EMBO J*, 10(12), 3905-11. [PUBMED](#)

H. Lederer, O. Schatz, R. May, H. Crespi, J. L. Darlix, S. F. Le Grice and H. Heumann. (1992). Domain structure of the human immunodeficiency virus reverse transcriptase. *EMBO J*, 11(3), 1131-9. [PUBMED](#)

O. Schatz, J. Mous and S. F. Le Grice. (1990). HIV-1 RT-associated ribonuclease H displays both endonuclease and 3'----5' exonuclease activity. *EMBO J*, 9(4), 1171-6. [PUBMED](#)

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, NIAID, NIH: HIV-1 p51 Reverse Transcriptase Recombinant Protein from Dr. Stuart Le Grice." Also include the references cited above in any publications.

Limited to two aliquots per lab per year. Larger amounts can be obtained upon request from the contributor.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the Director of Contracts and Tangible assets, Email: stacy.fening@case.edu, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated:

December 17, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.